Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 291

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 291
---
| ● | at least one year has elapsed from the time that the issuer filed current Form 10-type information with the SEC reflecting its status as an entity that is not a shell company. |

We are no longer a shell company and, as a result, once the conditions set forth in the exceptions listed above are satisfied, Rule 144 will become available for the resale of shares of Common Stock. Registration Rights Each of the Investor Rights Agreement, the Keystone Registration Rights Agreements, the Arena Purchase Agreement, the Fee Modification Agreements and the Liquidated Damages Modification Agreement provides for certain registration rights. For additional information, see the subsections entitled “ Description of Securities—Registration Rights.” 183 PLAN OF DISTRIBUTION We have engaged A.G.P./Alliance Global Partners, or the placement agent, to act as our exclusive placement agent to solicit offers to purchase the shares of our Common Stock, Pre-Funded Warrants and Offered Common Warrants offered by this prospectus pursuant to a placement agency agreement. The placement agent is not purchasing or selling any such securities, nor is it required to arrange for the purchase and sale of any specific number or dollar amount of such securities, other than to use their “reasonable best efforts” to arrange for the sale of such securities by us. Therefore, we may not sell all of the shares of Common Stock, Pre-Funded Warrants and Common Warrants being offered. The terms of this offering were subject to market conditions and negotiations between us, the placement agent and prospective investors. The placement agent will have no authority to bind us. This is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering. The placement agent may retain sub-agents and selected dealers in connection with this offering. We will enter into a securities purchase agreement directly with the purchasers, at the purchaser’s option, who purchase our securities in this offering. Purchasers who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers who enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The nature of the representations, warranties and covenants in the placement agency agreement shall include:

| ● | standard issuer representations and warranties on matters                                                                                 
 such as organization, qualification, authorization, no conflict, no governmental filings required, current in SEC filings, no litigation,